P6NP Stock Overview
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Acer Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$4.10 |
| 52 Week Low | US$0.55 |
| Beta | 0.44 |
| 1 Month Change | 8.84% |
| 3 Month Change | 17.61% |
| 1 Year Change | n/a |
| 3 Year Change | -64.50% |
| 5 Year Change | -96.19% |
| Change since IPO | -90.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| P6NP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.5% | -3.1% | -2.0% |
| 1Y | n/a | -31.9% | -0.3% |
Return vs Industry: Insufficient data to determine how P6NP performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how P6NP performed against the German Market.
Price Volatility
| P6NP volatility | |
|---|---|
| P6NP Average Weekly Movement | 35.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P6NP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine P6NP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 30 | Chris Schelling | www.acertx.com |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company’s pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.
Acer Therapeutics Inc. Fundamentals Summary
| P6NP fundamental statistics | |
|---|---|
| Market cap | €19.86m |
| Earnings (TTM) | -€36.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs P6NP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P6NP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.76m |
| Earnings | -US$38.76m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -96.4% |
How did P6NP perform over the long term?
See historical performance and comparison